Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Ulrich Keilholz(German Cancer Research Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Anne-Marie Geueke, Cornelis J.A. Punt(Utrecht University), T. M. Proebstle, R Salzmann, B. Hantich, Reinhard Dummer(University Hospital of Zurich), Carmen Scheibenbogen(University of Freiburg), S.H. Goey, Alexander Enk(Heidelberg University), D. Liénard, Dirk Schadendorf(National Center for Tumor Diseases)
Cited by 196
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k